Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Behavioral Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran Biomed J. 2022 Mar 1;26(2):110-5. doi: 10.52547/ibj.26.2.110.
Lithium is a therapeutic option for the treatment of the acute phase of the bipolar disorder and long-term management of this disorder. However, it is estimated that 10 to 60% of patients do not properly response to this medication.
To investigate the role of MARK2 gene in response to lithium, we genotyped the MARK2 rs10792421 polymorphism in Iranian bipolar patients using amplification Refractory Mutation System-PCR.
Results of this study showed a significant association of this polymorphism with response to lithium. The A allele was more frequent in the responder than the non-responder group and also in the semi- responder group compared to the non-responder group in the codominant model of analysis. AA and AG genotypes were more frequent in both the responder and semi-responder groups compared to the non-responder group in dominant model of analysis.
Based on the findings of the current study, the rs10792421 variant of MARK2 gene could be considered as a potential biomarker for predicting the treatment outcome of bipolar disorder type 1 in Iranian population.
锂是治疗双相情感障碍急性期和长期管理的一种治疗选择。然而,据估计,10%至 60%的患者对此药物没有适当反应。
为了研究 MARK2 基因在锂反应中的作用,我们使用扩增受阻突变系统-聚合酶链反应对伊朗双相情感障碍患者的 MARK2 rs10792421 多态性进行了基因分型。
这项研究的结果表明,该多态性与锂反应显著相关。与非反应组相比,应答组中 A 等位基因更为常见,与非反应组相比,半应答组中 A 等位基因也更为常见,在显性模型分析中。与非反应组相比,在显性模型分析中,AA 和 AG 基因型在应答组和半应答组中更为常见。
基于本研究的结果,MARK2 基因的 rs10792421 变体可以被认为是预测伊朗人群 1 型双相情感障碍治疗结果的潜在生物标志物。